Esperion Therapeutics Ownership
| ESPR Stock | USD 2.57 0.05 1.98% |
Shares in Circulation | First Issued 2000-03-31 | Previous Quarter 188.8 M | Current Value 194.9 M | Avarage Shares Outstanding 33 M | Quarterly Volatility 42.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Esperion |
Esperion Stock Ownership Analysis
About 66.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.67. Esperion Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 11th of June 2013. Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Esperion Theraptc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 218 people. To learn more about Esperion Therapeutics call Sheldon Koenig at 734 887 3903 or check out https://www.esperion.com.Esperion Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Esperion Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Esperion Therapeutics backward and forwards among themselves. Esperion Therapeutics' institutional investor refers to the entity that pools money to purchase Esperion Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Advisers, Llc | 2024-06-30 | 3.9 M | Meditor Group Ltd | 2024-09-30 | 3.8 M | State Street Corp | 2024-06-30 | 3.8 M | Two Sigma Investments Llc | 2024-09-30 | 3.6 M | Centerbook Partners Lp | 2024-09-30 | 3.1 M | Whitefort Capital Management, Lp. | 2024-06-30 | 2.3 M | Nuveen Asset Management, Llc | 2024-06-30 | 2.3 M | Jpmorgan Chase & Co | 2024-06-30 | 2 M | Rhenman Partners Asset Management Ab | 2024-09-30 | 2 M | Wasatch Advisors Lp | 2024-09-30 | 23.3 M | Blackrock Inc | 2024-06-30 | 14 M |
Esperion Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Esperion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Esperion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Esperion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Esperion Therapeutics Outstanding Bonds
Esperion Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Esperion Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Esperion bonds can be classified according to their maturity, which is the date when Esperion Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| ESPR 4 15 NOV 25 Corp BondUS29664WAB19 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Esperion Therapeutics Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Esperion Stock
| 0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.83 | AGL | agilon health Buyout Trend | PairCorr |
| 0.82 | ME | 23Andme Holding | PairCorr |
| 0.82 | NKTX | Nkarta Inc | PairCorr |
| 0.81 | MTEM | Molecular Templates | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.